gastroesophageal junction cancer

FDA Approves Opdivo Qvantig for Subcutaneous Injection

The FDA approved nivolumab plus hyaluronidase (Opdivo Qvantig, Bristol Myers Squibb) for an array of GI cancers.

JANUARY 8, 2025

FDA Grants New Indication for Opdivo for Resected Esophageal or GEJ Cancer

The FDA granted a new indication for nivolumab (Opdivo, Bristol Myers Squibb) for the treatment of patients with ...

JUNE 7, 2021

Load more